Periodic Reporting for period 3 - BeatsDigTherapeutics (Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders) Période du rapport: 2021-09-01 au 2022-08-31 Résumé du contexte et des objectifs généraux du projet Beats Therapeutics specialises in digital therapeutics for neurological and brain disorders. There are over a billion people worldwide living with a neurological or brain disorder. This has led to pressure on healthcare systems and payers to improve self-management and reduce long-term costs. The high risk and low approval rates of neuro-pharmaceuticals has led to billions of dollars of annual losses for the pharmaceutical industry. Many of these failures have been attributed to insufficient understanding of the brain. We deliver tailored assessments and therapy's for neurological and CNS disorders with the aim to improve care and reduce costs while developing a greater understanding of central nervous system conditions. Our core smart technology platform leverages data science and the advancements in smartphone technologies to deliver cost effective daily assessments and individually tailored therapy to patients in their own homes. Project SCALE will allow us to enhance our core technology applicability to rapidly deploy disease specific technologies for pharmaceutical industry and payer industry while enhancing our global impact on patients’ lives Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent Beats Therapeutics has scaled up it's Core Platform and developed the Beats Smart Platform to tailor therapies to meet patient needs. We have scaled up our backend and frontend systems to meet the enhanced requirements of the pharmaceutical, payer and healthcare industry. We have implemented enhanced integration capabilities and utilised ML and AI to transform our tailored delivery through both in it's design and therapeutic delivery. We have advanced our commercialisation content to meet the requirements of our changing B2B market and conducted extensive marketing research Our breakthrough technologies are now being clinically piloted in a number of hospitals in the US and EuropeWe have launched the product to the market and attained industry partnerships in the pharma and payer space Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent) The impact of Project Scale will be far reaching. Digital Therapeutics represent the next frontier in medicine, supporting patients in managing symptoms at home through advanced technologies. We aim to support over a billion people worldwide who are impacted by CNS conditions. We wish to support our users and their families access to therapies at home to promote their independence in the short term. In doing so we hope to reduce escalating healthcare costs while improving outcomes and broader access to care. In the long term, we aim to generate a greater understanding of these complex conditions to inform our disease understanding and new therapy development. We will work along side the healthcare, pharmaceutical and payer industry to transform disease management into the future. Documents connexes Logo_Blue.png
